Akero Therapeutics
Why Robinhood?
You can watch AKRO and buy or sell other stocks, ETFs, and their options commission-free!About AKRO
Akero Therapeutics, Inc. is a clinical-stage company, which engages in the development of treatments for patients with serious metabolic diseases. The firm's lead product candidate, efruxifermin (EFX), is an analog of fibroblast growth factor 21, or FGF21, which is an endogenously expressed hormone that protects against cellular stress and regulates metabolism of lipids, carbohydrates, and proteins throughout the body.
AKRO Key Statistics
Stock Snapshot
As of today, Akero Therapeutics(AKRO) shares are valued at $54.65. The company's market cap stands at 4.38B, with a P/E ratio of -14.58.
On 2026-03-06, Akero Therapeutics(AKRO) shares started trading at —, with intraday highs of — and lows of —.
Trading volume for Akero Therapeutics(AKRO) stock has reached 0, versus its average volume of 2M.
The stock's 52-week range extends from a low of $21.34 to a high of $58.40.
The stock's 52-week range extends from a low of $21.34 to a high of $58.40.
People also own
Similar Marketcap
This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.
Popular Stocks
This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset
Newly Listed
This list is generated by showing companies that recently went public.